1. Home
  2. GLU vs SGMO Comparison

GLU vs SGMO Comparison

Compare GLU & SGMO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Gabelli Global Utility of Beneficial Ownership

GLU

Gabelli Global Utility of Beneficial Ownership

N/A

Current Price

$19.12

Market Cap

119.8M

Sector

Finance

ML Signal

N/A

Logo Sangamo Therapeutics Inc.

SGMO

Sangamo Therapeutics Inc.

HOLD

Current Price

$0.18

Market Cap

141.2M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
GLU
SGMO
Founded
2004
1995
Country
United States
United States
Employees
N/A
N/A
Industry
Finance/Investors Services
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
119.8M
141.2M
IPO Year
N/A
2000

Fundamental Metrics

Financial Performance
Metric
GLU
SGMO
Price
$19.12
$0.18
Analyst Decision
Strong Buy
Analyst Count
0
3
Target Price
N/A
$7.00
AVG Volume (30 Days)
8.1K
90.5M
Earning Date
01-01-0001
05-07-2026
Dividend Yield
8.60%
N/A
EPS Growth
N/A
10.20
EPS
0.62
N/A
Revenue
N/A
$36,567,000.00
Revenue This Year
N/A
$107.15
Revenue Next Year
N/A
$76.44
P/E Ratio
$30.69
N/A
Revenue Growth
N/A
88.60
52 Week Low
$16.60
$0.12
52 Week High
$21.69
$0.77

Technical Indicators

Market Signals
Indicator
GLU
SGMO
Relative Strength Index (RSI) 42.81 37.98
Support Level $18.91 N/A
Resistance Level $20.17 $0.55
Average True Range (ATR) 0.33 0.03
MACD -0.03 -0.01
Stochastic Oscillator 62.20 34.48

Price Performance

Historical Comparison
GLU
SGMO

About GLU Gabelli Global Utility of Beneficial Ownership

Gabelli Global Utility & Income Trust is a non-diversified, closed-end management investment company. The Fund's objective is to seek a consistent level of after-tax total return. It predominantly invests in stocks of companies involved to a substantial extent in providing products, services, or equipment for the generation or distribution of electricity, gas, or water and infrastructure operations, and in equity securities including preferred securities of companies in other industries, in each case in such securities that are expected to pay periodic dividends.

About SGMO Sangamo Therapeutics Inc.

Sangamo Therapeutics Inc is a genomic medicine company committed to translating ground-breaking science into medicines that transform the lives of patients and families afflicted with serious neurological diseases. Its pipeline products include the Priority Neurology Pipeline offers Chronic Neuropathic Pain, Prion Disease, and Neurology; Partnered Programs offer Hemophilia A, Oncology, ALS/FTD, and Huntington's Disease; and Other Pipelines include Fabry Disease, Renal Transplant, Inflammatory Bowel Disease, and Multiple Sclerosis.

Share on Social Networks: